2397 |
Unment Needs and Alternatives to Clopidogrel in Patients with ACS Undergoing PCI |
Dominick J. Angiolillo |
May. 14. 13 |
2396 |
Drug-eluting Balloon Experience in Gachon University Gil Hospital |
Soon Yong Suh |
May. 14. 13 |
2395 |
Integrating Drug-eluting Balloon into Regular PCI Practice: Our Experience in Singapore |
Paul JL Ong |
May. 14. 13 |
2394 |
Drug-eluting Balloon: "Past, Present and the Future" |
Rosli Mohd Ali |
May. 14. 13 |
2393 |
Coronary Drug Coated Balloon Applications: Future Mainstream or Niche Device? |
Franz X. Kleber |
May. 14. 13 |
2392 |
Polyvascular Disease and the Broad Indication of Clopidogrel |
Young-Guk Ko |
May. 14. 13 |
2391 |
The Art of Balance in Clopidogrel: Efficacy vs. Safety |
Kyung Woo Park |
May. 14. 13 |
2390 |
How to Optimize PCI Outcomes in Daily Practice |
Bernard R. Chevalier |
May. 14. 13 |
2389 |
Current Korean Slender System for Optimizing Daily TRA and TRI |
Seung-Woon Rha |
May. 14. 13 |
2388 |
Percutaneous Treatment of LONG Native Coronary Lesions with Drug-Eluting Stent-V: Biolimus A9-Eluting (NOBORI) vs. Everolimus-eluting (PROMUS-ELEMENT) Stent: LONG V Trial Preliminary Data |
Seung-Whan Lee |
May. 14. 13 |